The story of HIV/AIDS treatment over the past three decades is one of the most remarkable in modern medicine. In the early 1990s, an HIV diagnosis carried a life expectancy measured in months. Today, a person diagnosed with HIV who starts treatment promptly, adheres to their regimen, and maintains regular follow-up has a life expectancy approaching that of the general population.
As a pulmonologist, Dr. Rajkumar Korra at Lalitha Chest and Skin Hospital frequently manages HIV-positive patients with pulmonary complications — opportunistic lung infections that remain the leading cause of illness and death among people living with HIV who are not yet on treatment or whose treatment is failing. This article is written for patients and families who want to understand the current treatment options and what they mean in practice.
How HIV Affects the Lungs
HIV progressively depletes CD4+ T-lymphocytes — the immune cells that coordinate the body's defence against infection. Below a CD4 count of approximately 200 cells/μL, the immune system is compromised severely enough that opportunistic infections occur. The lungs are among the most vulnerable organs.
Common HIV-related lung conditions include:
- Pneumocystis jirovecii pneumonia (PCP) — the most common serious opportunistic lung infection; presents with progressive breathlessness, dry cough, and fever
- Tuberculosis (TB) — HIV significantly increases both the risk of developing active TB from latent infection and the severity of disease
- Bacterial pneumonias — occur at higher frequency and with atypical organisms at low CD4 counts
- Pulmonary cryptococcosis and other fungal infections — in severely immunocompromised patients
These complications are preventable — and largely reversible — with effective antiretroviral therapy (ART).
Modern Antiretroviral Therapy: The Basics
ART works by suppressing HIV replication in the body, allowing the immune system to recover and preventing the CD4 count from falling to dangerous levels. It does not eliminate HIV from the body, but it renders the viral load in the blood undetectable — which protects the patient's own health and eliminates the risk of sexual transmission (U=U: Undetectable = Untransmittable).
Today's standard ART regimens have several important characteristics:
- Single-tablet, once-daily dosing — major regimens are now combined into one pill taken once a day, dramatically simplifying adherence compared to earlier multi-tablet regimens
- High genetic barrier to resistance — modern drugs (particularly integrase strand transfer inhibitors such as dolutegravir) are far more resistant to resistance mutations than older drugs
- Excellent tolerability — long-term side-effect profiles have improved substantially; most patients tolerate modern ART without significant issues
- Rapid viral suppression — most patients achieve an undetectable viral load within three to six months of starting treatment
When to Start and Who to Involve in Care
Current guidelines in India recommend initiating ART as soon as HIV is diagnosed, regardless of CD4 count. Earlier treatment is associated with better outcomes, lower rates of opportunistic infection, and reduced inflammation-driven complications (including cardiac, neurological, and renal disease).
HIV care involves a multidisciplinary team: an ART specialist (typically an infectious disease physician or government ART centre), a pulmonologist for respiratory complications, and other specialists as needed. Dr. Rajkumar Korra works within this framework, managing the chest and lung complications of HIV while coordinating with ART specialists for his patients' overall care.
Long-Acting and Emerging Therapies
The next frontier in HIV treatment is long-acting formulations — injectable ART administered monthly or bimonthly that eliminates daily pill-taking entirely. Cabotegravir + rilpivirine (monthly injectable) is already approved in several countries and is under evaluation in India. These regimens will be particularly significant for patients who struggle with daily adherence.
HIV prevention has also advanced significantly, with pre-exposure prophylaxis (PrEP) — a daily oral medication taken by HIV-negative individuals at high risk — reducing the risk of acquisition by more than 99% when taken consistently.
Coming Forward: Why It Matters
The greatest barrier to effective HIV care in India remains stigma and delayed presentation. By the time many patients reach us with a pulmonary complication, they have already lost years of immune function that could have been preserved with earlier treatment. There is no condition that benefits more from early, informed engagement with a healthcare team.
If you or someone you care for is living with HIV and experiencing any respiratory symptoms — persistent cough, unexplained breathlessness, fever that has not resolved — please contact Lalitha Chest and Skin Hospital at +91 94413 59200, Opp. Adharshnagar Board, Choppadandi Road, Karimnagar – 505001. Dr. Rajkumar Korra provides compassionate, confidential specialist care for all pulmonary complications.